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Background: Pre-diabetes and untreated diabetes are common in patients with peripheral artery disease however
their impact on outcome has not been evaluated. We examined the association of impaired fasting glucose,
diabetes and their treatment with the presentation, mortality and requirement for intervention in peripheral artery
disease patients.
Methods: We prospectively recruited 1637 patients with peripheral artery disease, measured fasting glucose,
recorded medications for diabetes and categorised them by diabetes status. Patients were followed for a median of
1.7 years.
Results: At entry 22.7% patients were receiving treatment for type 2 diabetes by oral hypoglycaemics alone (18.1%)
or insulin (4.6%). 9.2% patients had non-medicated diabetes. 28.1% of patients had impaired fasting glucose (5.6-6.9 mM).
Patients with non-medicated diabetes had increased mortality and requirement for peripheral artery intervention
(hazards ratio 1.62 and 1.31 respectively). Patients with diabetes prescribed insulin had increased mortality (hazard
ratio 1.97). Patients with impaired fasting glucose or diabetes prescribed oral hypoglycaemics only had similar outcomes
to patients with no diabetes.
Conclusions: Non-medicated diabetes is common in peripheral artery disease patients and associated with poor
outcomes. Impaired fasting glucose is also common but does not increase intermediate term complications. Peripheral
artery disease patients with diabetes requiring insulin are at high risk of intermediate term mortality.
Keywords: Peripheral artery disease, Diabetes, Mortality, Surgery, Patient managementBackground
Peripheral artery disease (PAD) represents a collection of
occlusive and aneurysmal diseases affecting the peripheral
arteries with an associated high risk of major cardiovas-
cular events and mortality [1]. There are recognised defi-
ciencies in current methods of predicting and limiting
complications in PAD patients [2,3]. Globally, an estimated
382 million people have diabetes and this number will rise
to 592 million in 2035 [4]. Diabetes is a recognised risk* Correspondence: jonathan.golledge@jcu.edu.au
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unless otherwise stated.factor for occlusive PAD development but is negatively
associated with peripheral aneurysm development [5-8].
Diabetes has been independently associated with mortality
in PAD patients in some but not all studies [9-13]. Recent
data suggest that ~10% of patients presenting with PAD
have untreated diabetes and ~17% have impaired fasting
glucose [14]. The effect of impaired fasting glucose and
untreated diabetes on PAD outcome is unknown. This
study aimed to examine the association of impaired fasting
glucose, diabetes and their treatments with the presenta-
tion, mortality and requirement for intervention of PAD
patients.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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An expanded methods section is provided in the Additional
file 1.
Study design and sample size
This study was part of on-going prospective cohort inves-
tigation of peripheral vascular disease patients aimed at
assessing risk predictors of peripheral vascular disease
presence and outcome [15,16]. Monte-Carlo simulations
suggest that a multivariate regression model is adequately
powered when using 10 outcome events per degree of free-
dom of the predictor variable [17]. We estimated that mor-
tality at one year would be ~10% and planned to adjust for
up to 15 variables in our regression model. This suggested
that ~1600 patients would provide sufficient power to
examine the association of diabetes with mortality.
Patients
Patients were recruited from in and out-patient vascular
services at The Townsville Hospital, The Mater Hospital
Townsville and The Royal Brisbane and Women’s Hospital,
Australia. Patients with all types of peripheral vascular dis-
ease were considered for inclusion as previously described
[15,18]. Inclusion criteria for the current study included a
diagnosis of PAD, assessment of fasting blood glucose and
at least one follow-up assessment as an in or out-patient.
This study was conducted in accordance with the Declar-
ation of Helsinki. Ethical approval for the study was granted
by the local Institutional Ethics Committees at The
Townsville Hospital, The Mater Hospital Townsville, The
Royal Brisbane and Women’s Hospital and James Cook Uni-
versity (61/05, MHS2006-01, H2196, 2007/004, 12/QTHS/
202, MHS20140114-01, H5206, 13/ QTHS/125). Partici-
pants provided written informed consent for inclusion.
Definitions and diagnosis of PAD
The current study included patients with occlusive or
aneurysmal disease of their peripheral arteries. Presenting
complaints included asymptomatic carotid stenosis, mild
lower limb or upper limb peripheral athero-thrombosis,
aneurysm of the aorta or peripheral arteries, symptomatic
carotid artery stenosis and critical lower limb ischaemia,
as previously described [15,16,18].
Assessment of fasting blood glucose and diabetes
Patients were asked if they were receiving medications for
the treatment of diabetes, specifically oral hypoglycaemics or
insulin. Patients provided blood samples after an overnight
fast for automated assessment of serum glucose as part of
their clinical care. Utilising clinical information and blood
glucose measurements, patients were grouped as follows:
a) No diabetes: Receiving no medications for diabetes
and fasting blood glucose <5.6 mM;b) Impaired fasting glucose: Receiving no medications
for diabetes and fasting blood glucose 5.6-6.9 mM;
c) Non-medicated diabetes: Receiving no medications
for diabetes and fasting blood glucose ≥7.0 mM;
d) Diabetes prescribed oral hypoglycaemics only:
Currently prescribed one or more oral
hypoglycaemic agents but not insulin for previously
diagnosed diabetes;
e) Diabetes prescribed insulin: Currently prescribed
insulin for previously diagnosed diabetes.
Definitions of other risk factors
Hypertension was defined by a history of high blood
pressure or receiving treatment to reduce blood pressure
[15,16,18]. Smoking status was classified as ever and
never smokers [15,16,18]. Coronary heart disease (CHD)
was defined by a history of myocardial infarction, angina
or treatment for coronary artery disease [15,16,18]. Esti-
mated glomerular filtration rate (eGFR) was calculated
using the Chronic Kidney Disease-Epidemiology Collab-
oration group (CKD-EPI) formula since we have previ-
ously found this to be most accurately associated with
complications in PVD patients [16].
Medications
In addition to anti-diabetic drugs, each patient’s medica-
tions were recorded including whether the participants
were prescribed a statin, aspirin, another anti-platelet agent,
a beta-blocker, a calcium channel blocker (CCB), an angio-
tensin converting enzyme (ACE) inhibitor, an angiotensin
receptor blocker (ARB) and frusemide [15,16,18].
Follow-up
Patients were followed up through attendance at out-
patient clinics and /or as an in-patient as part of their
normal medical care as previously described [15,16,18].
Recording of outcome data
The primary outcome was mortality. The secondary out-
come was requirement for a peripheral artery intervention.
Outcome data was recorded during clinical reviews on
prospectively defined report forms. Charts and hospital
electronic records of all patients were reviewed by a vascu-
lar specialist or clinical researcher. For peripheral artery
intervention assessments, patients were censored at the
time of the first intervention or at the date of last in/out
patient review or death if no intervention was required.
Statistical analyses
Nominal data are presented as numbers and percentages.
The association of diabetes categories with the clinical
presentation and risk factors of the patients was assessed
using Kruskal Wallis and chi-squared tests. The associa-
tions of diabetes categories with death and requirement
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Kaplan Meier estimates, log rank test and Cox propor-
tional hazard analyses. Cox proportional hazard analyses
were adjusted for varying combinations of risk factors
(age, sex, hypertension, ever smoking, CHD, presenting
complaint, statin prescription, aspirin prescription, other
anti-platelet prescription, beta blocker prescription, CCB
prescription, ACE inhibitor prescription, ARB prescrip-
tion, frusemide prescription and eGFR) across four differ-
ent models. These covariates were included as they are
recognised determinants of outcome for patients with car-
diovascular disease.
For Cox proportional hazards analyses, diabetes categor-
ies were defined as indicators in the following order: No
diabetes; impaired fasting glucose; non-medicated dia-
betes; diabetes prescribed oral hypoglycaemics only; and
diabetes prescribed insulin. Presenting peripheral artery
disease complaint was defined as indicators in the follow-
ing order: asymptomatic carotid stenosis; mild lower limb
or upper limb peripheral athero-thrombosis; aneurysm of
the aorta or peripheral arteries; symptomatic carotid artery
stenosis; and critical lower limb ischemia. Age and eGFR
were included in regression models as continuous num-
bers. Binary variables were defined as present or absent.
Results and discussion
Risk factors of the cohort
1637 PAD patients were included in the current study. The
presenting complaints of the patients included aortic or
peripheral aneurysms (n = 707; 43.2%), mild limb peripheral
artery disease (n = 381; 23.3%), symptomatic carotid artery
stenosis (n = 226; 13.8%), critical limb ischaemia (n = 184;
11.2%) and asymptomatic carotid artery stenosis (n = 139;
8.5%). The median age of the patients was 71 years and ap-
proximately three quarters were male (Table 1). Risk factors
for cardiovascular disease included a history of hyperten-
sion and smoking in 77% and 82%, respectively. Forty eight
percent of patients had a past history of diagnosis or treat-
ment of CHD.
Relationship between risk factors, presentation, impaired
fasting glucose, diabetes and its management
At entry 372 (22.7%) patients were receiving treatment for
type 2 diabetes by oral hypoglycaemics alone (n = 296;
18.1%) or insulin (n = 76; 4.6%). Fasting blood glucose
concentrations (≥7 mM) suggested diabetes in a further
150 (9.2%) patients who were on no medications for dia-
betes. A further 460 (28.1%) patients had fasting blood
glucose concentrations between 5.6 and 6.9 mM which we
defined as impaired fasting glucose. The other 655 (40.0%)
patients had a normal fasting blood glucose concentration
(<5.6 mM). Diabetes category was significantly associated
with age, hypertension, CHD, eGFR, and prescription of
statins, aspirin, beta blockers, CCBs, ACE inhibitors, ARBsand frusemide (Table 1). Patients with diabetes prescribed
insulin were younger, had lower eGFR and more com-
monly had a history of hypertension and CHD than those
with no diabetes (Table 1). Patients with diabetes pre-
scribed insulin were also more likely to be prescribed sta-
tins, beta blockers, CCBs, ACE inhibitors and frusemide
than those without diabetes (Table 1).
No difference in the prevalence of asymptomatic or
symptomatic carotid stenosis was observed between the
diabetes categories. Patients with non-medicated diabetes
were more likely to present with aortic or peripheral artery
aneurysms. Patients with diabetes who were prescribed in-
sulin more frequently presented with mild limb peripheral
artery disease and critical limb ischaemia.
Relationship between impaired fasting glucose, diabetes
and its management with mortality
Median follow-up time was 1.7 (interquartile range 0.5-4.1)
years. Three hundred and 17 (19.4%) patients died during
the follow up period. Kaplan Meier analyses suggested that
mortality was greatest in patients with diabetes prescribed
insulin who had an estimated mortality of 20.9% at 2 years
(Figure 1). Estimated mortality at 2 years in these patients
was greater than that of patients with no diabetes (10.6%;
p = 0.004), impaired fasting glucose (9.6%; p = 0.006) and
diabetes prescribed oral hypoglycaemics only (6.3%; p =
0.008). Estimated mortality at 2 years in patients with
non-medicated diabetes was similar to that of patients
with diabetes prescribed insulin (20.5%; p = 0.611). Cox
proportional hazard analyses suggested that, depending on
the other risk factors adjusted for, mortality increased 1.6-
1.7 fold in patients with non-medicated diabetes compared
to patients with no diabetes (Table 2). Similarly patients
with diabetes prescribed insulin had an increased mortal-
ity of 2.0-2.9 fold (Table 2). Patients with impaired fasting
glucose and diabetes prescribed oral hypoglycaemics only
had similar mortality to that of patients with no diabetes
(Table 2).
Relationship between impaired fasting glucose, diabetes
and its management with peripheral artery interventions
During follow up, 963 (58.8%) patients required a per-
ipheral artery intervention. Patients with non-medicated
diabetes were more likely to require a peripheral artery
intervention during follow-up (Figure 2). Kaplan Meier
analyses suggested that by two years after entry 69.3% of
these patients had required a peripheral artery inter-
vention. This intervention requirement was significantly
greater than for patients with no diabetes (57.4%; p =
0.008) and those with diabetes prescribed oral hypogly-
caemics only (57.1%; p = 0.018), and almost significantly
higher than for patients prescribed insulin (60.1%; p =
0.063). The intervention rate in patients with impaired
fasting glucose (63.9%; p = 0.210) was similar to that of
Table 1 Association of impaired fasting glucose, diabetes and their management with other cardiovascular risk factors,
medication prescription and presentation in 1637 patients with peripheral artery disease
Diabetes category
1 2 3 4 5 Total P value
Number 655 (40.0%) 460 (28.1%) 150 (9.2%) 296 (18.1%) 76 (4.6%) 1637
Age (years) 70.83 71.27 71.12 70.35 65.47 70.68 0.001
(63.28-76.98) (64.64-76.69) (66.19-76.91) (64.22-75.01) (59.74-72.07) (64.13-76.43)
Male 477 352 114 226 55 1224 0.591
(72.8%) (76.5%) (76.0%) (76.4%) (72.4%) (74.8%)
Hypertension 470 361 105 258 65 1259 <0.001
(71.8%) (78.5%) (70.0%) (87.2%) (85.5%) (76.9%)
Ever smoker 527 399 123 238 62 1349 0.074
(80.5%) (86.7%) (82.0%) (80.4%) (81.6%) (82.4%)
CHD 282 216 79 155 47 779 0.003
(43.1%) (47.0%) (52.7%) (52.4%) (61.8%) (47.6%)
eGFR (mL/min/1.73 m2) 76.39 73.37 74.22 74.93 69.17 74.93 0.040
(59.40-90.43)* (56.27-87.71)† (51.99-87.76)‡ (56.88-88.96)§ (44.47-91.02)|| (56.97-89.35)
Presenting complaint
Asymptomatic carotid stenosis 56 35 11 30 7 139 0.772
(8.5%) (7.6%) (7.3%) (10.1%) (9.2%) (8.5%)
Mild limb peripheral artery disease 151 91 25 89 25 381 0.001
(23.1%) (19.8%) (16.7%) (30.1%) (32.9%) (23.3%)
Aortic and peripheral artery aneurysm 302 225 84 88 8 707 <0.001
(46.1%) (48.9%) (56.0%) (29.7%) (10.5%) (43.2%)
Symptomatic carotid artery stenosis 90 70 15 43 8 226 0.491
(13.7%) (15.2%) (10.0%) (14.5%) (10.5%) (13.8%)
Critical limb ischaemia 56 39 15 46 28 184 <0.001
(8.5%) (8.5%) (10.0%) (15.5%) (36.8%) (11.2%)
Prescribed medication
Statin 392 325 92 232 61 1102 <0.001
(59.8%) (70.7%) (61.3%) (78.4%) (80.3%) (67.3%)
Aspirin 415 311 98 226 48 1098 0.003
(63.4%) (67.6%) (65.3%) (76.4%) (63.2%) (67.1%)
Other anti-platelets 130 90 37 72 21 350 0.194
(19.8%) (19.6%) (24.7%) (24.3%) (27.6%) (21.4%)
Beta-blockers 199 186 53 108 28 574 0.014
(30.4%) (40.4%) (35.3%) (36.5%) (36.8%) (35.1%)
Calcium channel blocker 155 142 50 99 27 473 0.004
(23.7%) (30.9%) (33.3%) (33.4%) (35.5%) (28.9%)
ACE inhibitor 227 182 58 153 52 672 <0.001
(34.7%) (39.6%) (38.7%) (51.7%) (68.4%) (41.1%)
ARB 142 94 34 94 17 381 0.005
(21.7%) (20.4%) (22.7%) (31.8%) (22.4%) (23.3%)
Metformin 0 0 0 245 40 285 <0.001
(82.8%) (52.6%) (17.4%)
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Table 1 Association of impaired fasting glucose, diabetes and their management with other cardiovascular risk factors,
medication prescription and presentation in 1637 patients with peripheral artery disease (Continued)
Other oral hypoglycaemic 0 0 0 170 26 196 <0.001
(57.4%) (34.2%) (12.0%)
Insulin 0 0 0 0 76 76 <0.001
(100%) (4.6%)
Frusemide 54 43 14 39 23 173 <0.001
(8.2%) (9.3%) (9.3%) (13.2%) (30.3%) (10.6%)
Serum creatinine was unavailable on 7*, 3†, 3‡, 1§ and 1|| patients therefore eGFR could not be calculated. CHD = coronary heart disease; ACE = angiotensin
converting enzyme; ARB = angiotensin receptor blocker; eGFR = estimated glomerular filtration rate. Continuous variables are presented as median and inter-quartile
range and assessed using the Kruskal Wallis test. Nominal variables are presented as number and percent and analysed using the Chi-squared test.
Key to patient groups:
1: No diabetes; 2: Impaired fasting glucose; 3: Non-medicated diabetes; 4: Diabetes prescribed oral hypoglycaemics only; 5: Diabetes prescribed insulin.
Golledge et al. Cardiovascular Diabetology 2014, 13:147 Page 5 of 9
http://www.cardiab.com/content/13/1/147patients with non-medicated diabetes (Figure 2). Cox
proportional hazard analyses suggested that the require-
ment for peripheral artery intervention was approxi-
mately 1.3-fold greater in patients with non-medicated
diabetes compared to those with no diabetes in different
models which included adjustment for other risk factors
(Table 3). The requirement for peripheral artery inter-
vention was similar in patients with impaired fastingFigure 1 Kaplan Meier curves showing the cumulative proportional m
for subjects grouped by diabetes categories. The blue, green, black, purple and
diabetes, diabetes prescribed oral hypoglycaemics only and diabetes prescribed
to follow-up.glucose, diabetes prescribed oral hypoglycaemics only,
diabetes prescribed insulin and no diabetes (Table 3).
Discussion
The current study has a number of important findings.
Firstly, impaired fasting glucose and diabetes are common
in patients with PAD. Only 40% of patients had normal
fasting glucose concentrations at entry and were notortality in relation to diabetes categories. Lines represent mortality
red lines represent no diabetes, impaired fasting glucose, non-medicated
insulin, respectively. Vertical lines represent subjects censored at loss
Table 2 Association of impaired fasting glucose, diabetes and their treatment with mortality in 1637 patients with
peripheral artery disease across 4 regression models
Model 1 Model 2 Model 3 Model 4
Patient group HR P value HR P value HR P value HR P value
(95% CI) (95% CI) (95% CI) (95% CI)
No diabetes 1.00 1.00 1.00 1.00
(reference) (reference) (reference) (reference)
Impaired fasting glucose 1.02 0.901 0.99 0.967 1.01 0.949 1.01 0.925
(0.77-1.35) (0.75-1.32) (0.76-1.35) (0.76-1.35)
Non-medicated diabetes 1.73 0.003 1.63 0.009 1.64 0.008 1.62 0.011
(1.21-2.48) (1.13-2.35) (1.14-2.37) (1.12-2.34)
Diabetes prescribed oral hypoglycaemics only 1.11 0.522 1.03 0.870 1.01 0.935 1.03 0.874
(0.80-1.54) (0.74-1.43) (0.72-1.43) (0.73-1.45)
Diabetes prescribed insulin 2.94 <0.001 2.28 0.001 1.98 0.006 1.97 0.007
(1.86-4.66) (1.42-3.66) (1.21-3.23) (1.20-3.23)
Models include the following covariates.
Model 1: Age and sex.
Model 2: Age, sex, hypertension, ever smoking, coronary heart disease and presenting complaint.
Model 3: Age, sex, hypertension, ever smoking, coronary heart disease, presenting complaint, statin prescription, aspirin prescription, other anti-platelet prescription, beta
blocker prescription, calcium channel blocker prescription, angiotensin converting enzyme inhibitor prescription, angiotensin receptor blocker prescription and
frusemide prescription.
Model 4: Age, sex, hypertension, ever smoking, coronary heart disease, presenting complaint, statin prescription, aspirin prescription, other anti-platelet prescription, beta
blocker prescription, calcium channel blocker prescription, angiotensin converting enzyme inhibitor prescription, angiotensin receptor blocker prescription, frusemide
prescription and eGFR. Please note, 15 patients with missing serum creatinine values were excluded from this analysis.
Figure 2 Kaplan Meier curves showing the cumulative proportional requirement for peripheral artery intervention in relation to
diabetes categories. Lines represent requirement for peripheral artery intervention for subjects grouped by diabetes categories. The blue, green,
black, purple and red lines represent no diabetes, impaired fasting glucose, non-medicated diabetes, diabetes prescribed oral hypoglycaemics
only and diabetes prescribed insulin, respectively. Vertical lines represent subjects censored at loss to follow-up.
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Table 3 Association of impaired fasting glucose, diabetes and their treatment with requirement for peripheral artery
intervention in 1637 peripheral artery disease patients across 4 regression models
Model 1 Model 2 Model 3 Model 4
Patient group HR P value HR P value HR P value HR P value(95% CI) (95% CI) (95% CI) (95% CI)
No diabetes
1.00 1.00 1.00 1.00
(reference) (reference) (reference) (reference)
Impaired fasting glucose
1.14
0.099
1.13
0.138
1.11
0.195
1.13
0.141
(0.98-1.33) (0.96-1.32) (0.95-1.30) (0.96-1.32)
Non-medicated diabetes
1.33
0.011
1.31
0.016
1.29
0.026
1.31
0.020
(1.07-1.66) (1.05-1.64) (1.03-1.61) (1.04-1.64)
Diabetes prescribed oral hypoglycaemics only
0.98
0.790
0.96
0.682
0.93
0.434
0.94
0.496
(0.81-1.17) (0.80-1.16) (0.77-1.12) (0.77-1.13)
Diabetes prescribed insulin
0.90
0.542
0.79
0.179
0.82
0.260
0.83
0.299
(0.65-1.25) (0.57-1.11) (0.58-1.16) (0.59-1.18)
Models include the following covariates.
Model 1: Age and sex.
Model 2: Age, sex, hypertension, ever smoking, coronary heart disease and presenting complaint.
Model 3: Age, sex, hypertension, ever smoking, coronary heart disease, presenting complaint, statin prescription, aspirin prescription, other anti-platelet prescription, beta
blocker prescription, calcium channel blocker prescription, angiotensin converting enzyme inhibitor prescription, angiotensin receptor blocker prescription and
frusemide prescription.
Model 4: Age, sex, hypertension, ever smoking, coronary heart disease, presenting complaint, statin prescription, aspirin prescription, other anti-platelet prescription, beta
blocker prescription, calcium channel blocker prescription, angiotensin converting enzyme inhibitor prescription, angiotensin receptor blocker prescription, frusemide
prescription and eGFR. 15 patients with missing serum creatinine values were excluded from this analysis.
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mately 28% of patients had fasting glucose concentrations
within the current definition for impaired fasting glucose
[19,20]. Approximately 23% of patients had been diag-
nosed with diabetes and were prescribed oral hypoglycae-
mics and/ or insulin. A further 9% of patients had fasting
glucose concentrations in the diabetes range and were
currently not prescribed oral hypoglycaemics or insulin.
Secondly, patients with non-medicated diabetes at entry
had higher mortality and increased requirement for per-
ipheral artery intervention compared to patients without
diabetes. Thirdly, patients with diabetes prescribed hypo-
glycaemics only had a similar mortality to patients with no
diabetes. Conversely patients with diabetes receiving insu-
lin had a ~2-3 fold increased risk of mortality compared
to patients with no diabetes.
PAD patients with non-medicated diabetes showed
higher rates of mortality and peripheral artery intervention
compared to patients with normal fasting glucose. The
exact reasons for this remain unclear but, may reflect poor
glycaemic control compared to patients receiving oral
hypoglycaemics. Previous data suggest that poor diabetes
control, evidenced by high HbA1c concentrations, is posi-
tively associated with major adverse events in patients
with established cardiovascular disease [21-23]. The rea-
sons that these patients were not receiving medications
for diabetes were not investigated here, although dietary
glycaemic management, a normal or mildly impaired pre-
vious oral glucose tolerance test or newly identified dia-
betes may be likely explanations. We also noted that these
patients were less likely to be receiving some othermedications like statins, aspirin and ACE inhibitors than
patients with diabetes on medication indicating that these
patients were receiving less secondary cardiovascular pro-
tection. It is possible these patients may have been less
willing to visit their local medical practitioner, or comply
with treatment advice. Two of the hospitals from which
participants were recruited have large rural Australian
catchment areas. A recent audit of rural aged care facilities
demonstrated that one third of residents with diabetes
were managed by diet alone and only 41% were managed
according to current diabetes guidelines [24]. Similar find-
ings have been reported in other rural health care audits
[25]. It is therefore possible that the outcomes of the
current study are reflective of management strategies used
by rural physicians although we did not directly study this.
Patients prescribed oral hypoglycaemics in the current
study had outcomes similar to those of patients that did
not have diabetes. The mortality of these patients was
similar to that of patients without diabetes. Previous data
indicate that oral hypoglycaemics, particularly metfor-
min, reduce the incidence of major adverse events in pa-
tients with cardiovascular disease [26,27]. More recent
evidence suggests that metformin might also improve
the outcome of cancer which is a common co-morbidity
in cardiovascular disease patients [28]. In contrast pa-
tients prescribed insulin had a 2-3fold increased mortal-
ity in the current study. These findings are in keeping
with other studies which have highlighted the high cardio-
vascular event rate of diabetes patients on insulin [29-32].
It has even been suggested that insulin use may increase
event rate and recent trials attempting to achieve tighter
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outcomes [33,34]. The poor outcome of patients requiring
insulin reported in the current study is likely multifactor-
ial, and in part probably reflects their poor glycaemic con-
trol. Recent data demonstrate marked differences in the
expression of several genes governing atherogenesis and
plaque instability in arterial biopsies collected from PAD
patients with good and poor glycaemic control [35]. The
complications of PAD patients with insulin-controlled dia-
betes appear to be greater although the exact reasons for
this requires further study.
The fasting blood glucose range which should be used
to define pre-diabetes is controversial [20,36,37]. Current
guidelines suggest that fasting blood glucose in the range
of 5.6 to 6.9 mM should be defined as impaired fasting glu-
cose and this was employed in the current study [20,36].
The frequency of impaired fasting glucose reported in the
current study (28%) is greater than that reported (17%) in
a recent study which focussed on patients with lower limb
athero-thrombosis [13]. In the latter study patients also
underwent oral glucose tolerance tests and it was noted
that impaired fasting glucose did not define the same
group of subjects as does an impaired response to a glu-
cose tolerance test [14]. Glucose tolerance tests were not
performed in the current study. It has been suggested that
the diagnosis of impaired fasting glucose overestimates the
burden of dysglycaemia [20,36]. It is relevant to note that
PAD patients with impaired fasting glucose had similar
mortality and requirement for peripheral artery interven-
tion as patients with normal fasting glucose in this study.
Study strengths and limitations
The current study has a number of strengths and weak-
ness. Strengths include the large sample size, the adjust-
ment for many potential confounding factors and the large
range of different peripheral artery disease complaints
studied. Weaknesses include the absence of information
on oral glucose tolerance tests, dietary management of dia-
betes or HbA1C. The overall follow-up of the patients was
also relatively short at a median of approximately 2 years.
Importantly, we were only able to collect clinical charac-
teristics of the included patients at the time of recruitment.
Hall and colleagues recently reported that altering anti-
glycaemic medication regime during a 3.5 year follow-up
significantly influences cardiovascular outcomes in pa-
tients with diabetes [31]. However, the design of the
current study limited the ability to accommodate changes
in risk factors which may have influenced cardiovascular
outcome in our patient cohorts. Finally, the cause of death
was not available and it is therefore possible that other
factors may have contributed to overall mortality in the
current study, complicating interpretation of our findings.
Future studies are required to specifically investigate the
relationship between diabetes presentation, managementand cardiovascular mortality in the northern Australian
PAD population.
Study conclusions
The findings of this work have important implications.
Firstly dysglycaemia is very common in PAD patients.
Screening newly referred patients for diabetes and where
appropriate referring them to a diabetes specialist would
appear appropriate as previously suggested [38]. Secondly,
patients with fasting blood glucose ≥7 mM not currently
receiving medication for diabetes are at increased risk of
major adverse events and may benefit from more intensive
management. Patients with established diabetes receiving
insulin are at particularly high risk of major adverse events
which should be considered in decisions about surgical
interventions.
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